- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947576
Intensive Case Management for Substance Use Disorders (RCT) (ICM)
Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial
This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.
Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).
Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.
In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:
- People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
- people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
- patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
- people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.
Sex and gender will be treated as potential covariates and will be considered in the analysis.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Johannes Senesi, MSc
- Phone Number: +41564622670
- Email: johannes.senesi@pdag.ch
Study Locations
-
-
Canton of Aargau
-
Windisch, Canton of Aargau, Switzerland, 5210
- Recruiting
- PDAG
-
Contact:
- Johannes Senesi, MSc
- Phone Number: +41564622670
- Email: johannes.senesi@pdag.ch
-
Principal Investigator:
- Johannes Senesi, Msc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 4 or more inpatient admissions in the last 24 months
- Diangosed SUD
- Residence or temporary stay in the canton of Aargau
Exclusion Criteria:
- any emergency situation requiring psychiatric or hospital admissions
- inability to give informed consent
- acute, unstable psychotic symptoms
- acute risk of harm to self or others
- insufficient german language skills
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental
receives ICM immediately |
Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:
|
|
Active Comparator: Waiting List
Same as Experimental, only with 6-Month TAU-Waiting List before ICM |
TAU will take place for 6 months before starting with ICM |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Inpatient Admissions (Health Service utilisation)
Time Frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Number of Inpatient Days (Health Service utilisation)
Time Frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WHOQoL-BREF
Time Frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Quality of Life |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
SFQ
Time Frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Social Functioning Questionnaire |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ASSIST
Time Frame: 6 Months (exploratory), 24 months (exploratory)
|
Substance use characteristics |
6 Months (exploratory), 24 months (exploratory)
|
|
Continuity of Care (Brice-Boxerman)
Time Frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Continuity of Care describes timeframes of the health services used outside the ward. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Linking
Time Frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Retention
Time Frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Retention describes the voluntary staying of patients in the ICM treatment |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
BSCL
Time Frame: 6 Months (exploratory), 24 months (exploratory)
|
Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care |
6 Months (exploratory), 24 months (exploratory)
|
|
EQ-5D-5L
Time Frame: 6 Months (exploratory), 24 months (exploratory)
|
EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER) |
6 Months (exploratory), 24 months (exploratory)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PDAG-ICM
- HumRes68440 (Other Identifier: Human Research Switzerland (HumRes))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.